What are PD-L1 inhibitors?
Table of Contents
What are PD-L1 inhibitors?
PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. However, the serious immune-related adverse reactions limited the clinical application of PD-1/PD-L1 monoclonal antibodies, despite the promising curative effects.
How does PD-1 immune checkpoint blockade therapy work?
When PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack. Monoclonal antibodies that target either PD-1 or PD-L1 can block this binding and boost the immune response against cancer cells.
What are Checkpoint targets?
Immune Checkpoint Targets: PD-L1 PD-L1 / B7-H1 / CD274 is the major ligand and expressed on hematopoietic cells including T cells, B cells, DCs, macrophages and mast cells as well as many nonhematopoietic cells including endothelial cells and numerous epithelial cells.
How do checkpoint inhibitors work?
Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells. One such drug acts against a checkpoint protein called CTLA-4.
Is Avastin a checkpoint inhibitor?
Tecentriq is the company’s anti-PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF, which plays a role in cancer by developing and maintaining blood vessels, in other words, angiogenesis.
What are checkpoint inhibitors and how do they work?
What is an example of a checkpoint inhibitor?
Examples of checkpoint inhibitors include pembrolizumab (Keytruda), ipilimumab (Yervoy), nivolumab (Opdivo) and atezolizumab (Tecentriq).
Where are checkpoint proteins located?
Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2. Some immune checkpoint inhibitors are used to treat cancer.
